Display options
Cite
Santorsola D, Abruzzese E. Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterr J Hematol Infect Dis. 2015;7(1):e2015020doi: 10.4084/MJHID.2015.020.
Santorsola, D., & Abruzzese, E. (2015). Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterranean journal of hematology and infectious diseases, 7(1), e2015020. https://doi.org/10.4084/MJHID.2015.020
Santorsola, Domenico, and Abruzzese, Elisabetta. "Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review." Mediterranean journal of hematology and infectious diseases vol. 7,1 (2015): e2015020. doi: https://doi.org/10.4084/MJHID.2015.020
Santorsola D, Abruzzese E. Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015020. doi: 10.4084/MJHID.2015.020. eCollection 2015. PMID: 25745547; PMCID: PMC4344172.
Copy Download .nbib Format: NLM
Share it on

Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015020. doi: 10.4084/MJHID.2015.020. eCollection 2015.

Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review.

Mediterranean journal of hematology and infectious diseases

Domenico Santorsola, Elisabetta Abruzzese

Affiliations

  1. Domenico Santorsola; MD, Servizio Dipartimentale di Ematologia ed Oncologia San Nicola Pellegrino Trani, Italy.
  2. Elisabetta Abruzzese, MD, PhD, Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy.

PMID: 25745547 PMCID: PMC4344172 DOI: 10.4084/MJHID.2015.020

Abstract

We report a case of a young patient with chronic viral hepatitis HBV infection, diagnosed with CML in March 2006 and treated with imatinib 400mg/die as first line therapy with concomitant Lamivudine. Patient obtained a complete hematologic response (CHR) in 2 months, complete cytogenetic response (CCyR) in six months and major molecular response (MMR) at 24 months. After three years of treatment, she became imatinib intolerant and resistant. In November 2009 patient started nilotinib 400mg/BID. Patient tolerated well the new molecule never experiencing hepatic impairment. After switching to nilotinib, she reached in 12 months transcript reduction more than 3 log (MMR). Even if patient had been informed of the need of continuous therapy and to use effective methods of contraception during tyrosine kinase inhibitor (TKI) treatment, in 2012 she decided to plan a pregnancy. In August 2012 a MR4 was documented, and treatment discontinued before starting pregnancy. She was placed on interferon and observed throughout her pregnancy. The disease remained stable achieving an undetectable transcript level; she delivered a healthy boy in September 2013. Treatment with nilotinib was re-started three months after delivery, and she is still in molecular remission (MR5). A complete discussion of the case and the available literature is presented.

References

  1. Lancet Oncol. 2010 Nov;11(11):1029-35 - PubMed
  2. Anticancer Drugs. 2012 Aug;23(7):754-7 - PubMed
  3. Leukemia. 2013 Jan;27(1):107-12 - PubMed
  4. Mediterr J Hematol Infect Dis. 2014 Apr 07;6(1):e2014028 - PubMed
  5. Blood. 2011 Jan 27;117(4):1141-5 - PubMed
  6. Am J Obstet Gynecol. 1991 Sep;165(3):565-6 - PubMed
  7. Science. 2004 Jul 16;305(5682):399-401 - PubMed
  8. Turk J Haematol. 2012 Dec;29(4):405-8 - PubMed
  9. Blood. 2013 Aug 8;122(6):872-84 - PubMed
  10. Fetal Diagn Ther. 1995 Jan-Feb;10(1):7-10 - PubMed
  11. Blood. 2008 Jun 15;111(12):5505-8 - PubMed
  12. Leukemia. 2009 Jun;23(6):1054-61 - PubMed
  13. Nat Med. 1996 May;2(5):561-6 - PubMed

Publication Types